[go: up one dir, main page]

DE60036937D1 - HUMANE GIL-19/AE289 PROTEINE UND DAFüR KODIERENDE POLYNUKLEOTIDE - Google Patents

HUMANE GIL-19/AE289 PROTEINE UND DAFüR KODIERENDE POLYNUKLEOTIDE

Info

Publication number
DE60036937D1
DE60036937D1 DE60036937T DE60036937T DE60036937D1 DE 60036937 D1 DE60036937 D1 DE 60036937D1 DE 60036937 T DE60036937 T DE 60036937T DE 60036937 T DE60036937 T DE 60036937T DE 60036937 D1 DE60036937 D1 DE 60036937D1
Authority
DE
Germany
Prior art keywords
gil
humane
proteins
polynucleotide coding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036937T
Other languages
English (en)
Other versions
DE60036937T2 (de
Inventor
Kenneth Jacobs
Lynette Fouser
Vikki Spaulding
Dejun Xuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22449618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60036937(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE60036937D1 publication Critical patent/DE60036937D1/de
Application granted granted Critical
Publication of DE60036937T2 publication Critical patent/DE60036937T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DE60036937T 1999-04-28 2000-04-28 HUMANE GIL-19/AE289 PROTEINE UND DAFüR KODIERENDE POLYNUKLEOTIDE Expired - Lifetime DE60036937T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13147399P 1999-04-28 1999-04-28
US131473P 1999-04-28
PCT/US2000/011479 WO2000065027A2 (en) 1999-04-28 2000-04-28 Human gil-19/ae289 proteins and polynucleotides encoding same

Publications (2)

Publication Number Publication Date
DE60036937D1 true DE60036937D1 (de) 2007-12-13
DE60036937T2 DE60036937T2 (de) 2008-08-07

Family

ID=22449618

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036937T Expired - Lifetime DE60036937T2 (de) 1999-04-28 2000-04-28 HUMANE GIL-19/AE289 PROTEINE UND DAFüR KODIERENDE POLYNUKLEOTIDE

Country Status (14)

Country Link
EP (2) EP1177312B1 (de)
JP (2) JP4828703B2 (de)
AT (1) ATE377077T1 (de)
BR (1) BR0010097A (de)
CA (1) CA2367965C (de)
CY (1) CY1107138T1 (de)
DE (1) DE60036937T2 (de)
DK (1) DK1177312T3 (de)
ES (2) ES2530857T3 (de)
MX (1) MXPA01010883A (de)
NZ (1) NZ515678A (de)
PT (1) PT1177312E (de)
WO (1) WO2000065027A2 (de)
ZA (1) ZA200109270B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016611A2 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
AU760224B2 (en) * 1998-10-26 2003-05-08 Wyeth Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
CA2367965C (en) * 1999-04-28 2015-12-01 Kenneth Jacobs Human gil-19/ae289 proteins and polynucleotides encoding same
AU2253301A (en) 1999-12-03 2001-06-12 Zymogenetics Inc. Human cytokine receptor
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
WO2001046422A1 (en) * 1999-12-23 2001-06-28 Zymogenetics, Inc. Novel cytokine zcyto18
ES2349312T3 (es) * 2000-07-27 2010-12-29 Wyeth Llc Uso de anticuerpos antagonistas del receptor de il-10 para inhibir la inducción por il-tif/il-21 de proteínas de fase aguda.
EP1337636B1 (de) 2000-08-08 2006-10-18 ZymoGenetics, Inc. Lösliche zcyctor 11 cytokinrezeptoren
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
CA2438238A1 (en) * 2001-02-23 2002-09-06 Genetics Institute, Llc. Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
AU2002252460A1 (en) 2001-03-27 2002-10-08 Zymogenetics, Inc. Human cytokine receptor
US7033787B2 (en) 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
US7265211B2 (en) 2002-03-22 2007-09-04 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of making
KR20050116392A (ko) 2003-03-24 2005-12-12 지모제넥틱스, 인코포레이티드 항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에 있어서의사용 방법
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
ES2696824T3 (es) 2005-05-31 2019-01-18 Univ Colorado Regents Métodos para suministrar genes
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5536637A (en) 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
AU677866B2 (en) 1993-08-26 1997-05-08 Board Of Trustees Of The University Of Illinois, The Neural regeneration using human bone morphogenetic proteins
ES2255059T3 (es) 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
US5679523A (en) 1995-11-16 1997-10-21 The Board Of Trustees Of The Leland Stanford Junior University Method for concurrent disruption of expression of multiple alleles of mammalian genes
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
AU760224B2 (en) * 1998-10-26 2003-05-08 Wyeth Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
CA2367965C (en) * 1999-04-28 2015-12-01 Kenneth Jacobs Human gil-19/ae289 proteins and polynucleotides encoding same
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
US20020187512A1 (en) * 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途

Also Published As

Publication number Publication date
JP2011160804A (ja) 2011-08-25
EP1177312A2 (de) 2002-02-06
HK1041021A1 (en) 2002-06-28
NZ515678A (en) 2004-01-30
DK1177312T3 (da) 2008-02-25
ZA200109270B (en) 2002-11-13
CA2367965A1 (en) 2000-11-02
WO2000065027A3 (en) 2001-04-05
ATE377077T1 (de) 2007-11-15
EP2357193A1 (de) 2011-08-17
WO2000065027A2 (en) 2000-11-02
ES2295026T3 (es) 2008-04-16
BR0010097A (pt) 2002-02-13
CA2367965C (en) 2015-12-01
CY1107138T1 (el) 2012-10-24
EP2357193B1 (de) 2015-11-04
JP4828703B2 (ja) 2011-11-30
ES2530857T3 (es) 2015-03-06
JP2003527078A (ja) 2003-09-16
MXPA01010883A (es) 2002-10-31
DE60036937T2 (de) 2008-08-07
EP1177312B1 (de) 2007-10-31
EP1177312A4 (de) 2004-08-25
PT1177312E (pt) 2008-01-22
HK1118576A1 (en) 2009-02-13

Similar Documents

Publication Publication Date Title
DE60036937D1 (de) HUMANE GIL-19/AE289 PROTEINE UND DAFüR KODIERENDE POLYNUKLEOTIDE
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
DK0409472T3 (da) Knoglemorfogenetisk protein
DE69939553D1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
DE69631544D1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
FI900808A0 (fi) Humant mannos bindande protein.
ATE487737T1 (de) 32 humane sekretierte proteine
ATE265226T1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten
ATE134219T1 (de) Menschliches mk gen und protein-sequenz
ATE126273T1 (de) Immunogenes protein und cdna-klon.
ATE218616T1 (de) Humanes zirkulierendes cytokin cc-1
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
DK0774004T3 (da) DNA-sekvens, som koder for de humane proteiner Tx og Ty, der er beslægtede med Interleukin-1betakonverterende enzym
EP1897950A3 (de) Humane GIL-19/AE289-Proteine und dafür kodierende Polynukleotide
MX9805158A (es) Adn que codifica una proteina activadora de plasminogeno.
DE69728936D1 (de) Polypeptid menschlicher Glykosaminglykan Sulfotransferase und dafür kodierende DNS
ATE329032T1 (de) Haemophilus influenza äusseres membranprotein und verwendung davon als impstoff
EP1425382A4 (de) Neue menschliche collagenproteine und diese codierende polynukleotide
FR2619910B2 (fr) Manipulateur analogique de parametres de son et de variation d'intensite lumineuse ou autres codages
SE9703137D0 (sv) Novel treatment of autoimmune diseases
ATE52277T1 (de) Immunogen-lage des poliovirus enthaltende peptide und dns enthaltend nukleotidfragmente die fuer diese peptide kodieren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition